BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32211961)

  • 1. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery.
    Hotta M; Minamimoto R; Gohda Y; Tajima T; Kiyomatsu T; Yano H
    Eur Radiol; 2020 Aug; 30(8):4193-4200. PubMed ID: 32211961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.
    Han X; Zhang Q; Zhou N; Ma R; Wang J; Zhai X; Cui B; Lu Y; Liang L
    Eur Radiol; 2023 Apr; 33(4):2800-2808. PubMed ID: 36418618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
    Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yoshizaki Y; Gohda Y; Inagaki F; Kataoka A; Takemura N; Miyazaki H; Igari T; Kiyomatsu T; Yano H; Kokudo N
    Clin J Gastroenterol; 2024 Feb; 17(1):188-197. PubMed ID: 37980306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 10. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
    Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
    van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
    BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
    Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
    Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
    Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
    Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
    Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score.
    Bouquot M; Dohan A; Gayat E; Barat M; Glehen O; Pocard M; Rousset P; Eveno C
    Ann Surg Oncol; 2018 Mar; 25(3):694-701. PubMed ID: 29192372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scalloping of the Liver and Spleen on Preoperative CT-Scan of Pseudomyxoma Peritonei Patients: Impact on Prediction of Resectability, Grade, Morbidity and Survival.
    Kepenekian V; Kefleyesus A; Keskin D; Benzerdjeb N; Bonnefoy I; Villeneuve L; Alhadeedi O; Al-Otaibi A; Galan A; Glehen O; Péron J; Rousset P
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
    Flood MP; Kong JC; Pham T; Waters PS; Soucisse M; Ramsay R; Wong HL; Mitchell C; Michael M; McCormick JJ; Warrier SK; Akhurst T; Heriot AG
    Eur J Surg Oncol; 2022 Jul; 48(7):1606-1613. PubMed ID: 35148916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.
    Dubreuil J; Giammarile F; Rousset P; Bakrin N; Passot G; Isaac S; Glehen O; Skanjeti A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1630-7. PubMed ID: 26907364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.